Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Han R, Wang Y, Lu L. Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics 2023, 16: 59. PMID: 38258070, PMCID: PMC10821464, DOI: 10.3390/pharmaceutics16010059.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMRNA vaccinesCheckpoint inhibitorsHCC treatmentEffectiveness of mRNAMRNA cancer vaccinesNovel mRNA vaccineSuppressive tumor microenvironmentHepatocellular carcinoma patientsCancer-associated antigensInnovative therapeutic strategiesCOVID-19 preventionCarcinoma patientsVaccine delivery vehiclesCancer vaccinesClinical evidenceHCC preventionTherapeutic strategiesVaccineTumor microenvironmentCancer treatmentPotential targetNew hopeTreatmentTrialsIn silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes